tetano
Editor, Senior Moderator
Vaccines (Basel). 2019 Oct 11;7(4). pii: E146. doi: 10.3390/vaccines7040146. [h=1]Evaluation of Pneumococcal Surface Protein A as a Vaccine Antigen against Secondary Streptococcus pneumoniae Challenge during Influenza A Infection.[/h]
Roberts S[SUP]1[/SUP], Williams CM[SUP]2[/SUP], Salmon SL[SUP]3[/SUP], Bonin JL[SUP]4[/SUP], Metzger DW[SUP]5[/SUP], Furuya Y[SUP]6[/SUP].
[h=3]Author information[/h] 1 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. SER80@pitt.edu. 2 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. williac10@amc.edu. 3 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. SalmonS@amc.edu. 4 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. boninj@amc.edu. 5 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. metzged@amc.edu. 6 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. furuyay@amc.edu.
[h=3]Abstract[/h] Secondary bacterial pneumonia is responsible for significant morbidity and mortality during seasonal and pandemic influenza. Due to the unpredictability of influenza A virus evolution and the time-consuming process of manufacturing strain-specific influenza vaccines, recent efforts have been focused on developing anti-Streptococcus pneumoniae immunity to prevent influenza-related illness and death. Bacterial vaccination to prevent viral-bacterial synergistic interaction during co-infection is a promising concept that needs further investigation. Here, we show that immunization with pneumococcal surface protein A (PspA) fully protects mice against low-dose, but not high-dose, secondary bacterial challenge using a murine model of influenza A virus-S. pneumoniae co-infection. We further show that immunization with PspA is more broadly protective than the pneumococcal conjugate vaccine (Prevnar). These results demonstrate that PspA is a promising vaccine target that can provide protection against a physiologically relevant dose of S. pneumoniae following influenza infection.
[h=4]KEYWORDS:[/h] Prevnar; Streptococcus pneumoniae; influenza-pneumococcal co-infection; pneumococcal surface protein A; pneumococcal vaccination
PMID: 31614565 DOI: 10.3390/vaccines7040146
Free full text
Roberts S[SUP]1[/SUP], Williams CM[SUP]2[/SUP], Salmon SL[SUP]3[/SUP], Bonin JL[SUP]4[/SUP], Metzger DW[SUP]5[/SUP], Furuya Y[SUP]6[/SUP].
[h=3]Author information[/h] 1 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. SER80@pitt.edu. 2 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. williac10@amc.edu. 3 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. SalmonS@amc.edu. 4 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. boninj@amc.edu. 5 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. metzged@amc.edu. 6 Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA. furuyay@amc.edu.
[h=3]Abstract[/h] Secondary bacterial pneumonia is responsible for significant morbidity and mortality during seasonal and pandemic influenza. Due to the unpredictability of influenza A virus evolution and the time-consuming process of manufacturing strain-specific influenza vaccines, recent efforts have been focused on developing anti-Streptococcus pneumoniae immunity to prevent influenza-related illness and death. Bacterial vaccination to prevent viral-bacterial synergistic interaction during co-infection is a promising concept that needs further investigation. Here, we show that immunization with pneumococcal surface protein A (PspA) fully protects mice against low-dose, but not high-dose, secondary bacterial challenge using a murine model of influenza A virus-S. pneumoniae co-infection. We further show that immunization with PspA is more broadly protective than the pneumococcal conjugate vaccine (Prevnar). These results demonstrate that PspA is a promising vaccine target that can provide protection against a physiologically relevant dose of S. pneumoniae following influenza infection.
[h=4]KEYWORDS:[/h] Prevnar; Streptococcus pneumoniae; influenza-pneumococcal co-infection; pneumococcal surface protein A; pneumococcal vaccination
PMID: 31614565 DOI: 10.3390/vaccines7040146
Free full text